Department of Hospital Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan.
J Sex Med. 2012 Jul;9(7):1782-8. doi: 10.1111/j.1743-6109.2012.02742.x. Epub 2012 Apr 30.
In our previous study, chronic vardenafil treatment improved erectile function soon after the end of the treatment in rats with acute arteriogenic erectile dysfunction (ED).
The aim of this study is to evaluate whether the effects of chronic vardenafil treatment persist after the end of treatment using rats with acute arteriogenic ED.
Rats were randomly divided into three groups: (i) control; (ii) ligation; and (iii) vardenafil + no treatment. Rats in the ligation and vardenafil + no treatment groups underwent ligature of the bilateral internal iliac arteries to induce acute arteriogenic ED and were subsequently treated with vehicle or vardenafil (4.0 mg/kg/day), respectively, for 3 weeks. Subsequently, all rats were kept for a further 2 weeks with no treatment. Rats in the control group underwent sham surgery.
Erectile function was assessed by changes in intracavernous pressure (ICP). Smooth muscle (SM)/collagen ratios in corpus cavernosum were analyzed by Masson trichrome staining. Transforming growth factor-β1 (TGF-β1 ) mRNA and protein levels in corpus cavernosum (CC) were, respectively, evaluated by real-time polymerase chain reaction (PCR) analysis and Western blotting analysis.
ICP/mean arterial pressure (MAP) in the ligation group remained significantly lower than that in control group (P < 0.01). Despite no treatment for 2 weeks, ICP/MAP in the var + no treatment group remained significantly higher than that in ligation group (P < 0.05). SM/collagen ratio in the ligation group remained significantly lower when compared with the control group (P < 0.01). The ratio in the var + no treatment group remained significantly higher when compared with the ligation group at 2 weeks after the end of treatment (P < 0.05). TGF-β(1) mRNA and protein levels did not differ among the groups.
The effects of chronic vardenafil treatment on erectile function and penile structure persist, even after the end of treatment, in acute arteriogenic ED rats.
在我们之前的研究中，慢性伐地那非治疗可改善急性动脉性勃起功能障碍（ED）大鼠治疗结束后不久的勃起功能。
本研究旨在评估慢性伐地那非治疗结束后，急性动脉性 ED 大鼠的治疗效果是否持续。
大鼠随机分为三组：（i）对照组；（ii）结扎组；（iii）伐地那非+无治疗组。结扎组和伐地那非+无治疗组大鼠双侧髂内动脉结扎，诱发急性动脉性 ED，分别用载体或伐地那非（4.0mg/kg/天）治疗 3 周。随后，所有大鼠均不进行治疗，继续观察 2 周。对照组大鼠行假手术。
通过海绵体腔内压（ICP）变化评估勃起功能。采用 Masson 三色染色分析海绵体平滑肌（SM）/胶原比。通过实时聚合酶链反应（PCR）分析和 Western blot 分析分别评估海绵体转化生长因子-β1（TGF-β1）mRNA 和蛋白水平。
结扎组 ICP/平均动脉压（MAP）仍显著低于对照组（P<0.01）。尽管治疗结束后 2 周未进行治疗，但伐地那非+无治疗组 ICP/MAP 仍显著高于结扎组（P<0.05）。结扎组 SM/胶原比仍显著低于对照组（P<0.01）。治疗结束后 2 周，伐地那非+无治疗组 SM/胶原比仍显著高于结扎组（P<0.05）。各组 TGF-β1 mRNA 和蛋白水平无差异。
慢性伐地那非治疗对勃起功能和阴茎结构的影响在急性动脉性 ED 大鼠中持续存在，甚至在治疗结束后。
